Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Vivo Capital

Investor type Private Equity Firm
Founders Edgar G. Engleman Frank Kung


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 177
Average round size
The average size of a deal this fund participated in
Portfolio companies 125
Rounds per year 6.81
Lead investments 27
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 74
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical

In 1997 was created Vivo Capital, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the Palo Alto.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vivo Capital, startups are often financed by Sofinnova Investments, OrbiMed, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Frazier Healthcare Partners, Aisling Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Aisling Capital, Technology Partners.

The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline ZAI Lab, Harmony Biosciences, Passage Bio Among the most popular fund investment industries, there are Medical, Genetics.

This organization was formed by Edgar G. Engleman. The overall number of key employees were 11.

Comparing to the other companies, this Vivo Capital performs on 11 percentage points more the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually. When the investment is from Vivo Capital the average startup value is 100-500 millions dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vivo Capital:
Typical Co-investors
Vivo Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vivo Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Actium Funds Salt Lake City, United States, Utah
Capital Fund Management France, Ile-de-France, Paris
Cognosante Mclean, United States, Virginia
Dingqing Investment Beijing, Beijing, China
Grit Ventures California, Menlo Park, United States
Kun Lun Stone Capital China, Guangdong, Shenzhen
MorphoSys Bayern, Germany, Planegg
New Science Ventures New York, New York, United States
NexGen Energy British Columbia, Canada, Vancouver
Pall New York, Port Washington, United States
Q Investments Fort Worth, Texas, United States
Rosario Capital LTD Israel, Tel Aviv, Tel Aviv District
RRC Group Moscow, Moscow, Russia
Rubicon Venture Capital California, San Francisco, United States
The Optimas Group Nebraska, Omaha, United States
TriplePoint Ventures California, Menlo Park, United States
Varsity Ventures California, Stanford, United States
Vertex Asia Fund Central, Central Region, Singapore
Xin Chang Electronics Technology -
Xuebao No.1 Beijing, China, Haidian

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$15M11 Aug 2022 Sao Paulo, São Paulo, Brazil


Health Care
$55M11 Jul 2022 New York, New York, United States


Electronic Health Record (EHR)
Health Care
$72M06 Jul 2022 Corona Del Mar, California, United States

Cerebral Therapeutics

Health Care
$40M28 Jun 2022 Aurora, Colorado, United States

DBV Technologies

Health Care
Health Diagnostics
$213M09 Jun 2022 Bagneux, Ile-de-France, France

Visirna Therapeutics

Health Care
$60M25 Apr 2022 Shanghai, Shanghai, China

Ocelot Bio

Health Care
Life Science
$36M23 Mar 2022 San Diego, California, United States

Avistone Pharmaceuticals

$200M08 Dec 2021 Beijing, Beijing, China

Ablaze Pharmaceuticals

$75M29 Nov 2021 Jingan, Shanghai, China
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vivo Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: